AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04044261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emotion induction using video
Description: Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
Study NCT01855685 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: X vivo gene therapy
Description: Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
Study NCT00738049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darusentan 100 mg
Description: All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
Study NCT00461786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 900 mg/m2, intravenous (IV), every 21 days, until disease progression
Study NCT02761512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50 mg QD
Description: CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
Study NCT02761512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100 mg QD
Description: CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
Study NCT02761512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30 mg QD
Description: Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
Study NCT01200810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01200810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT01200810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study NCT01200810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bicalutamide
Description: Given orally
Study NCT01200810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally
Study NCT04486794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane®
Description: Hyaluronic acid
Study NCT04486794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane®
Description: Hyaluronic acid
Study NCT04135235 — intervention group
Intervention type: DRUG
Intervention: TAF
Description: Propofol tenofovir fumarate
Study NCT04135235 — intervention group
Intervention type: DRUG
Intervention: TDF
Description: Dipirofurate fumarate tenofovir
Study NCT02897791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written evaluations
Description: answering questions about pictures and stories
Study NCT01194648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Study NCT01194648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: assessment of therapy complications
Study NCT01194648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high-intensity focused ultrasound ablation
Study NCT01194648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: multiparametric magnetic resonance imaging
Study NCT01194648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: quality-of-life assessment
Study NCT03904927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation, Surgery or Radiofrequency ablation
Description: Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
Study NCT03904927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: 1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy.
Study NCT03904927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: 1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy.
Study NCT01121289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1218
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study NCT01121289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study NCT01121289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1218
Description: 0.4 U/kg body weight injected subcutaneously (under the skin)
Study NCT04305392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: orally SHR4640
Study NCT01444716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT01717638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
Study NCT02800252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 plus aspirin before periodontal therapy
Description: Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
Study NCT03976700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei Jianpi granule
Description: Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
Study NCT03976700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bufei Jianpi granule
Description: Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
Study NCT00594555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
Study NCT00594555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG
Description: Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days
Study NCT02013414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D ultrasound-guided biopsy
Description: Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
Study NCT04288791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equia Forte Fil
Description: Glass hybrid innovation achieved through the introduction of ultrafine, highly reactive glass particles dispersed with conventional GI. The restoration is coated with Equia Forte coat which incorporates multi-functional monomer producing a tougher resin matrix. This system is designed as alternative of amalgam in posterior teeth.
Study NCT04288791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zirconomer Improved
Description: Zirconia reinforced GI, Glass Polyalkenoate restoration; it is designed to exhibit high strength where the glass component of this GI undergoes finely controlled micronization to achieve optimum particle size and characteristics .
Study NCT01580644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0187 prodrug
Study NCT02469909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Overnight observation
Description: patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
Study NCT02469909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-discharge evaluation
Description: After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
Study NCT02469909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: outpatient clinic follow ups
Description: all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
Study NCT02469909 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate decannulation
Description: the tracheostomy tube is removed at once
Study NCT02469909 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gradual tracheostomy tube decrease
Description: The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
Study NCT02451319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Endoscopic treatment of Kidney Stones
Study NCT02311478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T380A Intrauterine Copper Contraceptive
Description: The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
Study NCT01136915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol 370
Description: one time administration for PCI
Study NCT01136915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol 320
Description: Iodixanol 320 single injection for percutaneous coronary injection
Study NCT03148340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VIPS Monitoring
Description: Bioimpedance asymmetry
Study NCT03240380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: joint crisis plan
Description: Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare.
Study NCT03240380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: crisis card
Description: Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office.
Study NCT00954083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIR/Floortime
Description: Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
Study NCT00954083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care
Study NCT02120079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotemax
Description: Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
Study NCT02120079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
Description: Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
Study NCT02120079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: In Vivo Confocal Microscopy (IVCM)
Description: In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
Study NCT00983970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive video game cycling
Description: Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session.
Study NCT00983970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cycling to Music
Description: Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
Study NCT02962466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC-Test
Description: classification of the oocyte based on the expression pattern observed in the cumulus cells
Study NCT02819388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive counseling
Description: A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
Study NCT01430884 — intervention group
Intervention type: OTHER
Intervention: Aspirated Coronary Blood
Description: Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
Study NCT04940221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: Telephone delivered non-persuasive shared decision-making for lung cancer screening.
Study NCT00392041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 3mg qpm for 12 weeks
Study NCT00392041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill qpm for 12 weeks
Study NCT02272270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline with chemoradiation (temozolomide and radiation therapy)
Description: Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
Study NCT03474575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prevention
Description: The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
Study NCT05982119 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ActiMyo/Syde
Description: The two watches can be worn as wristwatch or placed near the ankle and on the wheelchair.~* Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months.~* Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months.~* Control subjects >4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion.~* Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion.
Study NCT03575156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Study NCT03575156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample
Description: 6 ml
Study NCT01670006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Nucleus Cochlear Implant System
Study NCT01081990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclobenzaprine
Description: Cyclobenzaprine 5 mg TID for 7 days
Study NCT01081990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclobenzaprine
Description: Cyclobenzaprine 5 mg TID for 7 days
Study NCT00230737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 0.4 mg
Study NCT00230737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 4.0 mg
Study NCT00230737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03776786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY014
Description: TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)
Study NCT03776786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo
Study NCT01717638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Description: 0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
Study NCT04372238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAPIDS Intervention
Description: RAPIDS intervention combines a behavioral intervention along with hands-on training to use fentanyl test strips.